Chelsea Therapeutics Intl Ltd fka CHIP

[surf1944]

Remember also that Chelsea Therapeutics (Nasdaq: CHTP) is scheduled to present at the Rodman & Renshaw 12th Annual Healthcare Conference this Wednesday at 11:40 AM ET. As we first told our subscribers in late August when the stock was trading at around $3.50, investors are anxiously awaiting news from CHTP’s pivotal Phase 3 trial with results due sometime this month. CHTP is currently completing work on Study 301 for the treatment of symptomatic, neurogenic orthostatic hypotension (NOH). Their latest PR regarding the study points to a results announcement sometime this month. Remember also that Chelsea has said that Study 302 would have received FDA approval, if they'd been using the new endpoints. This reaffirms our belief that Study 301 will show significant results in NOH. The stock closed at $ 4.04 following Monday's session after spiking as high as $4.26 following our initial report.

http://seekingalpha.com/article/225060-three-biotech-stocks-with-pending-news-developments-catalysts?source=yahoo